

# Veeral H Ajmera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299472/publications.pdf>

Version: 2024-02-01

38  
papers

2,015  
citations

346980

22  
h-index

388640

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3198  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.   | 6.1 | 45        |
| 2  | Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022, 18, 55-66.  | 4.3 | 82        |
| 3  | Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. <i>American Journal of Transplantation</i> , 2022, 22, 1699-1704.  | 2.6 | 33        |
| 4  | Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210938. | 1.4 | 18        |
| 5  | Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. <i>Clinical Infectious Diseases</i> , 2021, 72, 2124-2131.  | 2.9 | 16        |
| 6  | Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2673-2674.e3.   | 2.4 | 9         |
| 7  | Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. <i>Gastroenterology</i> , 2021, 160, 1620-1633.e13.   | 0.6 | 68        |
| 8  | Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021, 5, 786-797.  | 2.0 | 12        |
| 9  | RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. <i>Contemporary Clinical Trials</i> , 2021, 103, 106330.   | 0.8 | 9         |
| 10 | The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 68-77.   | 1.9 | 18        |
| 11 | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.   | 0.6 | 101       |
| 12 | Imaging biomarkers of NAFLD, NASH, and fibrosis. <i>Molecular Metabolism</i> , 2021, 50, 101167.   | 3.0 | 83        |
| 13 | Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. <i>Hepatology</i> , 2021, 74, 2241-2250.  | 3.6 | 41        |
| 14 | Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1718-1724.  | 0.4 | 16        |
| 15 | Machine learning enables new insights into genetic contributions to liver fat accumulation. <i>Cell Genomics</i> , 2021, 1, 100066.  | 3.0 | 34        |
| 16 | Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.  | 2.4 | 16        |
| 17 | Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 849-860.  | 3.6 | 57        |
| 18 | Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 744-746.e1.  | 2.4 | 26        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. <i>Liver International</i> , 2020, 40, 1111-1120.   | 1.9 | 7         |
| 20 | Refining Sample-Size Estimations Based Upon Placebo Response in Trials of Agents for Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 607-609.   | 2.4 | 3         |
| 21 | Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 477-479.e4.   | 2.3 | 4         |
| 22 | MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme A Desaturase Inhibitor (ARRIVE Trial). <i>Hepatology</i> , 2019, 70, 1531-1545.   | 3.6 | 33        |
| 23 | Medical Management after Liver Transplantation. <i>Digestive Disease Interventions</i> , 2019, 03, 305-313.   | 0.3 | 0         |
| 24 | Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 1884-1892.   | 6.1 | 48        |
| 25 | Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. <i>Journal of Hepatology</i> , 2019, 70, 126-132.  | 1.8 | 44        |
| 26 | Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 296-306.   | 2.4 | 121       |
| 27 | Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?. <i>Seminars in Liver Disease</i> , 2018, 38, 014-020.   | 1.8 | 21        |
| 28 | Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children?. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 341-342.  | 2.4 | 1         |
| 29 | Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 307-310.e2.                                  | 0.6 | 113       |
| 30 | Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1511-1520.e5. | 2.4 | 111       |
| 31 | Link between gut microbiome derived metabolite and shared gene effects with hepatic steatosis and fibrosis in NAFLD. <i>Hepatology</i> , 2018, 68, 918-932.   | 3.6 | 141       |
| 32 | Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. <i>Hepatology</i> , 2018, 67, 1348-1359.   | 3.6 | 250       |
| 33 | Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. <i>Hepatology</i> , 2017, 65, 2090-2099.  | 3.6 | 100       |
| 34 | Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. <i>American Journal of Gastroenterology</i> , 2017, 112, 755-762.  | 0.2 | 49        |
| 35 | Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 153, 1260-1272.e3.   | 0.6 | 57        |
| 36 | Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 65, 65-77.  | 3.6 | 134       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Nonalcoholic fatty liver disease activity score and mortality: Imperfect but not insignificant. Hepatology, 2016, 64, 309-310.                         | 3.6 | 2         |
| 38 | Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2016, 111, 658-664. | 0.2 | 80        |